03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
17:03 , May 25, 2018 |  BC Week In Review  |  Clinical News

Allergy Therapeutics reports Phase II data for grass pollen therapy

Allergy Therapeutics plc (LSE:AGY) said GrassMATA MPL met the primary endpoint of establishing a "dose-response relationship" in improving allergy symptoms as measured by the change in total symptom score (TSS) following a conjunctival provocation test...
04:13 , Dec 15, 2017 |  BC Week In Review  |  Company News

Allergy, Ergomed in allergy deal

Allergy Therapeutics plc (LSE:AGY) partnered with Ergomed plc (LSE:ERGO) to co-develop three of Allergy's OralVac subligual immunotherapy treatments. The OralVac products are marketed in Germany and other European countries on a named-patient basis, in which...
21:22 , Nov 10, 2017 |  BC Week In Review  |  Clinical News

Allergy Therapeutics begins Phase II trial of grass pollen allergy vaccine

Allergy Therapeutics plc (LSE:AGY) started the Phase II G205 trial of Pollinex Quattro Grass in about 440 patients with grass pollen allergy. The company told BioCentury it expects data in 2H18. The double-blind, placebo-controlled, European...
20:35 , Apr 18, 2017 |  BC Extra  |  Clinical News

Circassia abandoning allergy field after Phase IIb miss

Circassia Pharmaceuticals plc (LSE:CIR) said it will no longer develop allergy therapeutics following the failure of dust mite program HDM-SPIRE in a Phase IIb trial. The company plans to focus on its respiratory business, including...
13:03 , Mar 17, 2017 |  BC Week In Review  |  Clinical News

Pollinex Quattro Birch: Ph III B301 started

Allergy Therapeutics began the double-blind, placebo-controlled, European Phase III B301 trial to evaluate 900, 2,400 and 6,000 standardized units/mL subcutaneous Pollinex Quattro Birch in about 562 patients. Allergy Therapeutics plc (LSE:AGY), London, U.K.  Product: Pollinex...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

GrassMATAMPL: Phase II data

Top-line data from the double-blind, dose-ranging, U.S. Phase II G204 trial in about 265 patients with seasonal allergic rhinoconjunctivitis showed that a recommended Phase III dose of subcutaneous GrassMATAMPL was not determined. Patients received placebo;...
01:28 , Jun 28, 2016 |  BC Extra  |  Clinical News

Allergy Therapeutics grass pollen program hits snag

Allergy Therapeutics plc (LSE:AGY) lost 3.50p (15%) to 20p on Monday after it said it would need to conduct another dose-ranging study of grass allergy therapy GrassMATAMPL next year before beginning a U.S. Phase III...
07:00 , May 16, 2016 |  BC Week In Review  |  Clinical News

Pollinex Quattro Birch: Phase II data

Allergy Therapeutics said top-line data from the double-blind, placebo-controlled, European Phase II PQBirch204 trial in 371 patients with birch pollen-induced seasonal allergic rhinitis showed that 5,000-27,300 standardized units (SU) of subcutaneous Pollinex Quattro Birch met...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Clinical News

GrassMATAMPL: Completed Phase IIb enrollment

Allergy Therapeutics completed enrollment of 250 patients with seasonal allergic rhinoconjunctivitis exposed to grass pollen in the double-blind, placebo-controlled, U.S. Phase II G204 trial evaluating cumulative doses of 5,100, 10,200 and 18,200 standardized units (SU)...